Memantine Eg (Memantine)

Memantine works by binding to the NMDA‑type glutamate receptor as a non‑competitive antagonist. This blocks excessive calcium entry into neurons caused by over‑activation of the receptor, reducing excitotoxic damage and helping to stabilise neuronal communication in Alzheimer’s disease.

The dosing regimen for memantine is individualized. A qualified prescriber determines the appropriate dose based on the patient’s clinical condition, response, and tolerability, following local prescribing guidelines.

Safety data for memantine during pregnancy and lactation are limited. It should only be used when the potential benefit to the mother outweighs any possible risk to the fetus or infant, and the decision should be made by a healthcare professional.

To order Memantine Eg, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

The primary alternative class for Alzheimer’s disease is acetylcholinesterase inhibitors such as donepezil. While both classes aim to improve cognition, memantine targets glutamatergic excitotoxicity, whereas acetylcholinesterase inhibitors enhance cholinergic transmission. Clinical choice depends on disease stage, patient tolerance and physician assessment.

Memantine Eg should be stored at room temperature, below 25 °C. Keep the product in its original packaging, protect it from moisture and direct light, and ensure the container is tightly closed to maintain stability.

Memantine Eg is taken orally. The tablet (or other oral form) should be swallowed whole with water and can be taken with or without food, as directed by the prescribing clinician.

Serious adverse events include seizures, hallucinations, cardiac arrhythmias, severe skin reactions such as Stevens‑Johnson syndrome, suicidal thoughts, and liver injury. Patients should seek immediate medical attention if any of these symptoms occur.

Memantine should be avoided in individuals with known hypersensitivity to the drug, severe renal impairment without dose adjustment, or those concurrently receiving other NMDA‑receptor antagonists. Clinicians should also assess risks in patients with uncontrolled cardiovascular disease or a history of seizures.